INTRODUCTION
Multiple myeloma (MM) is a plasma cell malignancy characterized by abnormal proliferation of clonal plasma cells in the bone marrow (BM), typically accompanied by the secretion of defective monoclonal immunoglobulins (1) . Current therapies that have improved the outcome of patients include the proteasome inhibitor bortezomib and immunomodulatory drugs such as thalidomide and lenalidomide (2) . Nevertheless MM remains an incurable disease with a high rate of relapse and development of drug resistance, and a median survival of less than 5 years (3). The BM microenvironment plays a pivotal role in MM proliferation, survival, migration, and resistance to drugs, protecting cells from the cytotoxic effects of chemotherapy and radiation treatment (4) . The genetic and epigenetic heterogeneity in MM also contributes to relapse, and accordingly finding a druggable oncogenic process common in all patients has not yet been achieved (5) .
One of the common genetic alterations in MM is the overexpression of the histone methyltransferase enhancer of zeste homolog 2 (EZH2) (6) . EZH2 is, along with its paralogue EZH1, the catalytic subunit of Polycomb repressive complex 2 (PRC2), and is responsible for the methylation of histone H3 lysine 27 (H3K27) (7) . Methylation of H3K27 is associated with transcriptional repression, and it plays a critical role in regulating genes that determine the balance between cell differentiation and proliferation.
Normal BM plasma cells do not express EZH2, however, gene expression is induced and correlates with tumor burden during progression of MM (6) . While EZH2 controls H3K27 methylation in MM cells, inactivating mutations and deletions of the H3K27 demethylase lysine (K)-specific demethylase 6A (KDM6A, UTX) are frequent in MM (8) , further contributing to H3K27 aberrant hypermethylation of genes. Enzymes controlling methylation on histone H3 lysine 36 (H3K36), such as histone methyltransferase multiple myeloma SET domain (MMSET), can additionally regulate H3K27 methylation levels and distribution across the genome in MM (9) . In cells with high levels of MMSET, EZH2 is unable to bind and methylate sites with increased H3K36me2, and is relocated to loci that maintain H3K27 methylation (10) . Around 20% of MM cases have MMSET overexpression due to the genomic translocation t(4;14) (11) , placing the MMSET gene under the regulation of strong immunoglobulin enhancers, leading to abnormally high levels of H3K36me2 (12) and a concomitant reduction in H3K27 tri-methylation (H3K27me3) (13) . Thus overexpression of MMSET results in a shift of EZH2 function with a reduction of global levels of H3K27me3 and a localized gene specific increase of H3K27me3. Taken together, frequent genetic alterations of EZH2, UTX and MMSET disrupt the global and/or gene-specific balance of H3K27 methylation in MM.
Changes in the H3K27 methylation pathway have emerged as a recurrent phenomenon in many types of cancer, demonstrating that either excess or lack of H3K27 methylation can have oncogenic effects in different indications (14) . In MM it has been shown that PRC2 target genes are most often found silenced in myeloma (15) . Exploration of EZH2 inhibitors in MM models is therefore an attractive field of research which may lead to a broader understanding of MM biology and will guide the development of new targeted therapies.
Intensive efforts devoted to developing therapeutic approaches to target EZH2 function led to the discovery of small molecules that specifically inhibit EZH2. First molecules that directly target EZH2 and compete with the cofactor S-adenosylmethionin (SAM) binding have been described. The inhibitor E7438 has shown efficacy in SMARCB1 mutant Rhabdoid tumors (16) and as well as GSK126 and other reported EZH2 inhibitors (17, 18) , in EZH2-mutant non-Hodgkin lymphoma (19) where activating mutations are described (20) . In addition effects of EZH2 inhibitors in melanoma (21), ovarian tumors (22) , cervical cancer (23) and, mixed lineage leukemia (MLL) (24, 25) have been reported. Three first generation EZH2 inhibitors have recently entered phase I clinical trials (26) . In this study we propose that EZH2 plays an important role in MM development and progression. EZH2 inhibition promotes an anti-proliferative effect on a subset of MM cells, and we provide one possible mechanism by which EZH2 inhibition achieves cell growth inhibition in a cell line panel of various MM models. 
MATERIALS AND METHODS

Cell
Antibodies and Materials
Primary antibodies used in this study: H3K27me3, H3K36me2, EZH2 (Cell Signaling #9733, #2901, #5246), total histone H3, MMSET, JMJD3, anti-phosphoS5 RNA Pol II (Abcam ab10799, ab75359, ab154985, ab5408), UTX (BETHYL A302-374A), E-Cadherin (BD Biosciences 610182), EMP1 (Santa Cruz sc-55717) and GAPDH (Advanced Immunochem #RGM2). Secondary antibodies used: goat anti-mouse/rabbit IRDye 800 CW (LI-COR Biosciences), Alexa Fluor 680 goat anti-mouse/rabbit IgG and Rabbit anti-Goat IgG, antirabbit Alexa Fluor 680, anti-mouse Alexa 488 (Life technologies), and SULFO-TAG anti-rabbit/mouse (Meso Scale Discovery). E7438, CPI169, GSK126 and GSK343 were synthesized in house. Cells (in triplicate) were treated with dilution series of E7438 from 16μM to 0.125μM, or with DMSO and were incubated for 3 and 7 days. Proliferation was quantified using AlamarBlue® (Thermo Fisher Scientific) and fluorescence signal was detected with a VICTOR™ X3 Multilabel Plate Reader.
Proliferation Assays
Western Blot
Cells were lysed in RIPA buffer with Benzonase and protease inhibitors (Roche Diagnostics). Proteins were separated on SDS-PAGE gels and blotted onto nitrocellulose membranes. Experiments were performed in triplicate. Bands were detected and quantified with LI-COR Odyssey® Fc Software.
Enzyme-linked immunosorbent assay (ELISA)
Histones were extracted using the EpiXtract™ Total Histone Extraction Kit (Enzo) and added to 96-well ELISA Standard Plates (Meso Scale Discovery) in triplicate. After overnight incubation, plates were blocked with Blocker A Kit and incubated with the respective antibodies. Read Buffer T 4x was added prior to the measurement in SECTOR Imager 6000 (Meso Scale Discovery).
Gene expression analysis
Cells (2x10 5 per well) were seeded into six-well culture plates 24h before treatment. Five replicate wells were then exposed to 2μM of E7438 or DMSO for 3 days. RNA was extracted using RNeasy kit (Qiagen).
For each sample, 250ng of total RNA was amplified using the Affymetrix GeneChip WT PLUS Reagent Kit according to the protocol described in User Manual Target Preparation for GeneChip Whole Transcript (WT) Expression Arrays (P/N 703174 Rev. 2). An Affymetrix Human Gene 2.1 ST 96-array plate was hybridized with 3μg of fragmented and labeled ss cDNA, washed, stained, and scanned according to the protocol described in the User Manual GeneTitan®Instrument User Guide for Expression Arrays Plates 
Cell imaging
Cells were seeded in CellCarrier-384 Black Optically Clear Bottom plates (PerkinElmer) 24h before the treatment with 2μM of E7438 or DMSO, and cultured for 5 days. Transmitted light images were acquired with a 10x-magnification with a Molecuar Devices ImageXpress Micro widefield imaging system.
Immunofluorescence staining was done with cells attached to Chamber Slides (Thermo Fisher Scientific) treated with Poly-L-Lysine . Cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton™ X-100 and blocked with 1.0% bovine serum albumin. Staining was done using specific antibodies.
DAPI and Actin-fluorescent Alexa Fluor 568 (Life technologies) were used for nuclear and cytoplasmic staining, respectively. Images were acquired with an LSM700 confocal microscope (Zeiss) using 63x-magnification.
xCELLigence adhesion quantification
Cells were seeded into 96 wells e-plates (Acea Biosciences) 24h before the treatment. Cells (in triplicate)
were treated with 2 μM of E7438 and DMSO. Adhesion was monitored by impedance measurement every 15 min using the RTCA MP Station (Acea Biosciences).
Multiple myeloma xenograft mouse model
Animal experiments were conducted in accordance with the German animal welfare law, approved by inoculation. E7438 or vehicle (PEG400/EtOH 90/10) was administered p.o. BID at 250 and 500 mg/kg.
Tumor size was measured 2-3 times a week for 16 days. For RNA and protein extraction, tumor samples were immediately frozen in liquid nitrogen and stored at 80°C. Frozen tumors were mechanically homogenized using the TissueLyser and Stainless Steel Beads (Qiagen) and RNA and proteins were extracted as described above.
RESULTS
EZH2 inhibition induces time-dependent anti-proliferative effects in several MM cell lines
A total of 13 MM cell lines were selected for the initial set of experiments to characterize EZH2 inhibition which might reflect the complexity of possible protein products from the MMSET gene (13) . However, each of these cell lines presented high amounts of H3K36me2 combined with low levels of H3K27me3, and the inverse occurred for the cell lines without the t(4;14) translocation, confirming results also reported by others (27) . The protein levels of EZH2 and JMJD3 (another H3K27me3 specific demethylase not reported to be altered in MM) showed slight differences, which did not correlate with global H3K27me3 levels ( Figure 1A ).
To determine the effects of EZH2 inhibition on this panel of cell lines, they were treated with increasing concentrations of the E7438 for 3 and 7 days, and cell proliferation was measured ( Figure 1B A more pronounced effect of EZH2 inhibition on proliferation on day 7 is expected and can be explained by the mode of action of EZH2 inhibition. H3K27me3 loss precedes the transcriptional activation needed for proliferation defects. We and others have observed that the H3K27me3 mark has slow turnover kinetics (18) and a 2-3 day inhibition period is needed for significant demethylation (19, 28) .
To investigate the underlying mechanism of proliferation inhibition, effects on the cell cycle were measured after treatment with E7438 for 7 days (Supplementary Figure S2C) . Cell lines were treated with E7438 at the calculated IC50 value from proliferation assays, in order to compare the cycle effects at a similar inhibition level. We observed a general decrease in the percentage of cells in G2/M accompanied by an increase in sub-G1 (apoptotic) cells, except for the U-266 cell line which showed only a minor increase in the G0/G1 fraction. Similar results for apoptosis induction were obtained by analyzing the Annexin V/propidium iodide positive cells (Supplementary Figure S2D) . Next, we analyzed the effects of EZH2 inhibition on histone modifications. Global H3K27me3 levels were quantified by western blot after 3 days of treatment with 0.5 and 2 μM E7438, or DMSO as control. While only a subset of cell lines showed an effect on cell proliferation in response to E7438, H3K27me3 levels were reduced after E7438 treatment in a dose dependent manner in all tested MM cell lines, already at 3 days with 0.5 μM E7438 ( Figure 1C and Supplementary Figure S2E) . In order to obtain more quantitative data on the effect of E7438, we performed H3K27me3 and H3K36me2 ELISA on extracted histones. To re-confirm that H3K27me3 de-methylation does not always result in proliferation effects we also tested three other EZH2 inhibitors (GSK126, GSK343 and CPI169) in KMS-11 (Supplementary Figure S3A) .
Notably all inhibitors showed comparable target inhibition with an almost complete reduction in total H3K27me3 methylation with 2 μM after 3 days of treatment (Supplementary Figure S3B) . No proliferation effects were observed in KMS11 for any inhibitor used. GSK126 and GSK343 showed some additional proliferation effects with higher concentrations (>7.5 μM), but which could not be connected to an improved methylation inhibition in comparison to E7438 or CPI169 (Supplementary Figure S3B) .
Together our data reveal that E7438 reduces H3K27me3 levels in all tested MM cell lines, without significant changes in H3K36me2, causing a time-dependent anti-proliferative response in a subset of MM cell lines. Figure S2E) . Therefore addiction to the H3K27me3 methylation mark for transcriptional regulation seems to be variable between MM cell lines.
In a deeper analysis of all overlapping gene probes significantly changed specifically in RPMI-8226 and MOLP-8, we found 91 probes upregulated in common and no common probes downregulated ( Figure 2B and C). Gene ontology analysis showed enrichment of different pathways ( Figure 2D ), a major one being related to cell structure, adhesion and migration. To characterize further the underlying molecular mechanisms of EZH2 inhibition in MM, we focused in the next set of the experiments on the MOLP-8 cell line that had the highest number of significant transcriptional changes. To validate the expression screen results, we selected a subset of 12 upregulated genes for qRT-PCR analysis. Genes were selected from enriched categories of the gene ontology analysis, and were mostly related to cell adhesion. Each gene was confirmed to be upregulated after treatment with E7438 ( Figure 2E ). Results were independently 
confirmed with an additional EZH2 inhibitor, GSK126 (Supplementary Figure S4A) . Additionally, we observed that these genes showed a clear tendency for upregulation in all tested cell lines, regardless of if their sensitivity to E7438 in the proliferation assay ( Figure 2F ) and despite the limited overlap observed comparing all cell lines (Supplementary Tables S1A and B) . These results showed significant transcriptional activation after E7438 treatment in MM cell lines, revealing that most of the upregulated genes were related with cell structure, adhesion and migration.
E7438 induces local reduction of H3K27me3 at the promoter region of epithelial tumor suppressor genes
To further explore the regulation of the selected adhesion-related genes by EZH2, we analyzed gene specific H3K27me3 levels by Chromatin Immunoprecipitation (ChIP) and their expression at the protein level. In order to correlate the expression changes with the local loss of H3K27me3, ChIP experiments were performed. Enrichment of H3, H3K27me3, or phosphorylated RNA Pol II after ChIP was quantified in different regions surrounding the transcription start site (TSS) of CDH1, EMP1, VCAN, EPHB2 and ENPP1 genes, while GAPDH served as a control. H3K27me3 occupancy significantly decreased at all analyzed genes after E7438 treatment ( Figure 3A) .The basal levels of H3K27me3 before treatment in upregulated genes were high compared to GAPDH, indicating that they were potentially EZH2 targets marked by H3K27me3. A decrease of H3K27me3 in the promoter region of these genes after E7438 treatment presumably would allow for an increased binding of RNA Pol II and the initiation of transcription. Accordingly, we detected significant enrichment of RNA Pol II in the promoter region of analyzed genes after treatment ( Figure 3A) . These results confirmed the transcriptional activation Figure S4B) . Western blot experiments demonstrated that the observed upregulation at the transcription level was translated to an increase also at the protein level.
We observed more than double the protein levels of E-cadherin (CDH1 gene) and EMP1, two key adherence-related proteins, in MOLP-8 cell treated with E7438 in comparison to the DMSO control ( Figure 3B ). We conclude that global loss of H3K27me3 was also observed at the gene-specific level and led to an increased expression of mRNA and protein.
EZH2 inhibition increases adhesion of MM cells by morphological changes
Most of the upregulated genes from the expression analysis were described as epithelial tumor suppressor genes closely connected to adhesion and a more epithelial phenotype (29) . Therefore we speculated that their re-expression could increase adherence properties in MM cells. We closely Figure 5A ) and tumor weight ( Figure 5B) ) compared to the vehicle control group, with no effect on mouse body weight (Supplementary Figure S6) . Additionally, levels of H3K27me3 were measured within the tumor tissue. Western blot showed reduced levels of H3K27me3 in both treated groups at 250 and 500 mg/kg ( Figure 6A ). Quantitative detection by ELISA showed that levels of H3K27me3 in the 500mg/kg treated mice were significantly lower compared with mice treated at 250 mg/kg ( Figure 6B ). 
DISCUSSION
Multiple myeloma is a plasma cell malignancy for which there is no pharmacologic treatment that leads to a cure (3). Therefore establishment of new therapies for this disease could be a valuable addition to current treatment options (31) . MM is characterized by widespread dissemination of the BM with multiple focal lesions which requires the disruption of cell adhesive functions to invade new regions through systemic re-circulation (32) . Alterations in histone modifying enzymes like EZH2/UTX/MMSET have been frequently observed and point towards a potential driving role of epigenetic reprogramming of MM (33) . We uncovered an anti-proliferative activity of EZH2 inhibition in vitro in a set of MM cell lines and translated these findings to an in vivo xenograft model. Treatment with an EZH2 inhibitor resulted in upregulation of gene expression, which generally correlates with the role of EZH2 as a transcriptional repressor (34) . MOLP-8 and RPMI-8226 cell line models showed the most significant upregulation of genes, which also translated to robust inhibition of proliferation. But expression changes (with the threshold levels and assay conditions employed in our study) did generally not completely correlate with proliferation effects (Figure 2A) . This observation is different from reports in lymphoma cell lines where a direct correlation between expression profiles and the IC50 in proliferation assays has been observed for GSK126 (20) . This difference indicates a complex underlying genetic diversity in MM 
model systems. Different genetic and epigenetic drivers are potentially necessary to drive malignant transformation and are needed for cell proliferation.
For the H3K27 methylation/PRC2 pathway, several different gene mutations leading to elevated levels of methylation and gene repression have been proposed to predict a potential addiction to EZH2 activity in cancers (14, 35, 36) . Particularly in MM, several alterations have been proposed to be directly correlated with sensitivity to EZH2 inhibition. MMSET overexpression and UTX loss of function mutations have been proposed in previous studies (8, 9) , to lead to aberrant H3K27 methylation and transcriptional repression in MM. However, in our study we did not find a clear correlation of EZH2 inhibitor sensitivity with a distinct genetic mutational profile. Only the RPMI-8226 cell line from the five UTX mutated cell lines showed a significant response in gene expression and proliferation. In the t(4;14) positive cell lines we could confirm reports of globally increased levels of H3K36 methylation and decreased levels of H3K27 methylation (13) . Despite significant gene upregulation in some of the t(4;14) positive cell lines after treatment with E7438 only KMS-28BM showed a proliferation response. A potential limitation of our proliferation results could be the experimental assay system used. Three-dimensional cultures approximating physiological conditions have been proposed for EZH2 inhibitors to fully cover potential effects of epigenetic re-programming (21, 37) . Nevertheless our gene expression profiling after loss of global H3K27me3 is different for cell lines having comparable genetic alterations. Therefore genetic alterations predicting sensitivity to EZH2 inhibition remain elusive and further studies are needed.
We describe for the first time to our knowledge a potential role for EZH2 in the regulation of adherence and epithelial-mesenchymal differentiation genes in MM. EZH2 has been generally proposed to be critical for the regulation of epithelial-mesenchymal transition (EMT) associated master genes in cancer (38, 39) . We identified several genes involved in adherence, which showed a general trend for upregulation in all analyzed models (see Figure 2F ). Our data, together with recent publications in additional indications such as melanoma (21) MM is characterized by widespread dissemination of the BM at diagnosis, with multiple focal lesions in the BM, re-circulation into the peripheral blood, and re-entrance or homing of MM cells into new sites promoting metastasis (32) . Our study suggests that EZH2 might play an important role in shaping the interactions between MM cells and the micro-environment, regulating their adherence and their capacity to migrate. That EZH2 inhibition promotes adherence properties in MM cells could be beneficial, because it might prevent MM cell dissemination and new colonization within the BM, thus abrogating metastasis. One of the most important drivers in EMT is the downregulation of E-cadherin, which has been observed to be directly repressed by EZH2 in cancer (39) . The E-cadherin gene, CDH1, is upregulated in almost all the cell lines tested in this study, independent of their response to treatment.
During epithelial to mesenchymal transition, cells lose polarity and cell-cell adhesion, and gain migratory and invasive properties. Some examples uncovered in our study regulating similar processes are EMP1 (epithelial membrane protein 1). Reduced levels of EMP1 were associated with tumor invasion, lymph node metastasis, clinical stage and cell differentiation (43) (44) (45) . EMP1 is an integral tetraspan membrane protein whose function has been recently described to be involved in epithelial tight junction formation.
EPHB2 is a receptor tyrosine kinase from the ephrin family which is involved in multiple critical aspects of cell adhesion and migration and a putative tumor suppressor (46) . (47) . Another example is DOCK9 (dedicator of cytokinesis 9), which belongs to the Dock family of evolutionarily conserved exchange factors for the Rho GTPases Rac and Cdc42, regulating actin cytoskeleton, cell adhesion and migration (48) . SLFN5, a protein, was described to have a key role in controlling motility and invasiveness of renal cell carcinoma and melanoma cells (49, 50) . SLFN5 negatively controls expression of matrix metalloproteinases (MMPs), and several other genes involved in the control of malignant cell motility. 
